C8orf59 Inhibitors
The chemical class termed C8orf59 Inhibitors encompasses a diverse set of compounds targeting specific cellular pathways associated with the protein. Sunitinib, a receptor tyrosine kinase inhibitor, can impact multiple receptors, potentially influencing signaling pathways associated with C8orf59. Wortmannin inhibits PI3K, disrupting the PI3K/Akt pathway, while PD98059 inhibits MEK1, an upstream regulator of ERK1/2, and U0126 inhibits MEK1/2, potentially disrupting the MAPK/ERK signaling cascade linked to C8orf59.
BAY 11-7082 inhibits NF-κB activation, influencing inflammatory responses and cellular processes associated with C8orf59. SB-216763, a GSK-3 inhibitor, modulates Wnt/β-catenin signaling, and LY294002 inhibits PI3K, potentially affecting downstream events linked to C8orf59. Rapamycin inhibits mTOR, disrupting the mTOR signaling pathway, and SP600125 inhibits JNK, impacting MAPK signaling, both potentially influencing cellular processes related to C8orf59. GDC-0941 is another PI3K inhibitor, and SB-431542 inhibits the TGF-β type I receptor, potentially affecting TGF-β signaling and indirectly influencing cellular processes associated with C8orf59. SP2509, as a BRD4 inhibitor, may indirectly affect the expression of C8orf59. Collectively, these inhibitors form a class with diverse mechanisms, collectively influencing cellular processes associated with C8orf59.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, targeting multiple receptors. Inhibition of these receptors may impact signaling pathways associated with C8orf59. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. Inhibition of PI3K disrupts the PI3K/Akt signaling pathway, potentially influencing cellular processes linked to C8orf59. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1, an upstream regulator of ERK1/2. Inhibition of MEK1 disrupts the MAPK/ERK pathway, potentially affecting cellular events associated with C8orf59. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, a key transcription factor. Inhibition of NF-κB signaling may impact inflammatory responses and cellular processes associated with C8orf59. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB-216763 is a glycogen synthase kinase 3 (GSK-3) inhibitor. Inhibition of GSK-3 can impact Wnt/β-catenin signaling, potentially influencing cellular processes associated with C8orf59. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key components of the MAPK/ERK pathway. Inhibition of MEK1/2 may disrupt the MAPK/ERK signaling cascade, potentially influencing cellular processes related to C8orf59. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, disrupting the PI3K/Akt pathway. Inhibition of PI3K can potentially affect downstream events associated with C8orf59. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, disrupting the mTOR signaling pathway. Inhibition of mTOR can potentially impact cellular processes linked to C8orf59. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), impacting MAPK signaling. Inhibition of JNK may potentially affect cellular processes related to C8orf59. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a PI3K inhibitor, disrupting the PI3K/Akt signaling pathway. Inhibition of PI3K can potentially influence downstream events linked to C8orf59. | ||||||